Ahead of disease
Innovation is at the heart of achieving our purpose: to unite science, technology and talent to get ahead of disease together.
Scroll to explore
How our R&D approach helps us get Ahead Together
There’s never been a time when science and technology have formed such a powerful union as they do now. We’re able to identify drug discovery targets using genomics and AI/ML in a way that is unprecedented. We’re also able to use more approaches than ever before to design new vaccines and medicines to address the root cause of disease.
Globally, we’re driven to positively impact the health of over 2.5 billion people in the next 10 years. To deliver on our purpose, we must continue to discover and develop world-leading vaccines and medicines that can treat and prevent disease at scale.
We’re combining the power of genetic and genomic insights into what causes disease, with the speed and scale of artificial intelligence and machine learning (AI/ML) to make better predictions about who a treatment might work for, and why.
We believe this powerful combination of data and technology holds the key to fundamentally transforming medical discovery for the better, improving R&D success rates and shaping how even the most challenging diseases, like neurological conditions and cancer, can be both prevented and treated.
Our R&D investment in 2021£5.3bn
An outstanding R&D team of15k
Leading R&D in India
In India, over the past 50 years we have successfully launched a broad range of innovative medicines and vaccines that have reached millions of people around the world.
OUR GLOBAL INNOVATIONS:
As a global biopharma leader, we invest heavily in our industry-leading pipeline of new products that help us to get ahead of disease together.
Globally, the four areas of human health we focus on to get ahead of disease are: infectious diseases, HIV, oncology and immunology. We also remain open to opportunities outside these core areas where the science aligns with our strategic approach.
We are at the forefront of health-related advances in science and technology, working to create innovative solutions to a range of healthcare challenges.
Advanced technology platforms such as artificial intelligence (AI), machine learning (ML) and functional genomics are central to our R&D approach. At the same time, diverse vaccine platform technologies including the use of adjuvants and mRNA technology have the potential to drive the next generation of vaccines and medicines.
In India, our clinical trials are governed by strict regulation. Throughout each trial the proceedings are monitored by government authorities as well as GSK’s own Global Safety Board (GSB). There are always at least three phases to clinical trials. Occasionally a fourth phase might be necessary if:
- we think the medicine can be improved
- we need to provide answers to questions from the regulatory authorities
Find out about our clinical trials process, how we work with doctors and volunteers throughout this process, and how to become a research volunteer.
Our leading R&D centres in the UK, US, Belgium and Italy are pivotal in helping us to get ahead of disease around the world.